Navigation Links
CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients
Date:11/21/2008

ave psoriasis(2), a distressing chronic inflammatory disease. Approximately 80 per cent of these patients have plaque psoriasis, which is characterised by red, scaly patches.(3) Psoriasis can be extremely distressing, and may have a significant impact on patients' quality of life. It is a condition which is frequently physically and psychologically disabling.(4)

Currently, treatments for children and adolescents with psoriasis are mainly limited to topical medications that are applied directly to the skin. Whilst these treatments may be effective at reducing the visible skin lesions and associated symptoms, they are generally used for mild and moderate forms of paediatric psoriasis.

Enbrel is an innovative drug that works by reducing the chronic inflammation that leads to plaque psoriasis.

To access further media information relating to this press release, additional information on Enbrel and future media announcements, please register on the media centre athttp://www.wyeth.eu. If you subscribe to receive our emails you will get updates as soon as new content added to the site. Please note you will be able to unsubscribe at any time and we will not pass your details to any third party.

Notes To Editors

"The 211 study: Enbrel(R) in children and adolescents(5)

The 48 week study involved 211 patients with moderate-to-severe psoriasis aged four to 17 years. During the first 12 weeks of the trial, patients received once weekly injections of either placebo or 0.8 mg of Enbrel per kilogram of body weight up to a maximum of 50 mg. For the next 24 consecutive weeks, all patients went on to receive Enbrel. The 138 patients still participating at week 36 were then re-randomised to receive either placebo or Enbrel in order to investigate whether stopping treatment would lead to any rebound.

At week 12, almost tw
'/>"/>

SOURCE Wyeth Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Task Force Recommends Screening for Hearing Loss in All Newborns
2. FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
3. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
4. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
5. CHMP Recommends Expanded Use of Angiox(R) (Bivalirudin) in Europe for Patients With Acute Coronary Syndromes
6. Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds
7. Berlin Hearts EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
10. Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial
11. Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... field of regenerative medicine, today announced that the ... Chicago -based Rush University Medical Center in ... escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) in ... cervical spinal cord injury (SCI). This represents the ...
(Date:8/31/2015)... 2015   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... media and a related cloud hosted ... smart shippers ("BioLife" or the "Company"), today ... biopharmaceutical company focused on developing and commercializing novel ...
(Date:8/28/2015)... , Aug. 28, 2015  With the heroin ... reaching deadlier heights, Jacksonville -based Lakeview ... Hemphill is helping to explain why fentanyl is ... approximately 40 to 50 times more potent than pharmaceutical ... users as heroin, the risk of death skyrockets. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2
... (OTCQX: DATA), a technology and services company focused on global ... its Vice President of Research and Development, Chris Wilke, has ... 2009 Society for Clinical Data Management (SCDM) Annual Conference which ... Mr. Wilke will be discussing Is 100% EDC Realistic? ...
... ThermalTherapeutic Systems, Inc., developers of a highly ... today the completion of $2.75 Million Series A ... funding by the Pittsburgh Life Sciences Greenhouse, and ... investments by the Pittsburgh Life Sciences Greenhouse and ...
Cached Medicine Technology:DATATRAK to Present at 2009 SCDM Annual Conference 2DATATRAK to Present at 2009 SCDM Annual Conference 3ThermalTherapeutic Systems Completes $2.75 Million Series A Financing With Originate Ventures 2
(Date:8/31/2015)... ... , ... The Lisle family law firm of Momkus McCluskey, LLC ... peers to earn a “Leading Lawyers” distinction. , The “Leading Lawyers” ... Illinois. The nomination process is based on statewide peer survey nominations and the approval ...
(Date:8/31/2015)... ... August 31, 2015 , ... Patients who thought about getting a hair ... in learning more about the procedure beyond the information found on the Internet can ... transplant surgeon Parsa Mohebi will be on hand to answer patients hair transplant questions ...
(Date:8/31/2015)... ... 2015 , ... Neuropsychiatric Disease and Treatment has ... near-infrared laser phototherapy ”. , As corresponding author Dr Theodore Henderson says “These ... with mostly palliative treatments only - and now we have shown real clinical ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dr. Paul Kovatis of ... Doc.” , At OSSMC, Dr. Kovatis treats all surgical and non-surgical disorders of the ... to the entire musculoskeletal system, excluding the spine. , Dr. Paul Kovatis completed his ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... marketing communications company announced today that it has officially launched a new website ... new website and brand refresh are more closely aligned with the company’s strategic ...
Breaking Medicine News(10 mins):Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3
... the management of breast ... BRIDGEWATER, N.J., Dec. 7 Among the 62 oral,abstracts ... Symposium (SABCS), six with Taxotere(R) (docetaxel) Injection,Concentrate investigational regimens will ... Lecture 1 on the opening day of the symposium will ...
... - How do the lifestyle choices we make ... the American Association for Cancer Researchs Sixth Annual ... being held from December 5 to 8 in ... questions regarding daily decisions in diet, exercise, smoking ...
... eating four or more servings of green salad a week ... smokers and nonsmokers alike may be able to substantially reduce ... University of Texas M. D. Anderson Cancer Center. , "This ... of diet and physical activity on the possibility of developing ...
... Studies find effects on breast, prostate and colorectal tumors ... diabetes -- risk factors so often linked to heart ... of cancer, a collection of four new studies suggests. ... for Cancer Research,s Sixth Annual International Conference on the ...
... Data on Perifosine in the Treatment of Patients ... on Saturday, December 8th at 5:30pm, NEW ... KERX ) today announced that abstracts related to ... poster sessions,scheduled to take place at the upcoming ...
... The teams of Eric Le Cam, from,the ... - Institut Gustave,Roussy/CNRS/Universite Paris Sud) and David ... and Pathological Biomolecules - SABNP" lab,(Inserm/Universite d,Evry-Val-d,Essonne, ... method for observing DNA using atomic force,microscopy ...
Cached Medicine News:Health News:New Taxotere(R) (docetaxel) Injection Concentrate Data to be Presented at the 30th Annual San Antonio Breast Cancer Symposium (SABCS) 2Health News:New Taxotere(R) (docetaxel) Injection Concentrate Data to be Presented at the 30th Annual San Antonio Breast Cancer Symposium (SABCS) 3Health News:New Taxotere(R) (docetaxel) Injection Concentrate Data to be Presented at the 30th Annual San Antonio Breast Cancer Symposium (SABCS) 4Health News:New Taxotere(R) (docetaxel) Injection Concentrate Data to be Presented at the 30th Annual San Antonio Breast Cancer Symposium (SABCS) 5Health News:Lifestyle and cancer prevention: Making choices that change cancer risk 2Health News:Lifestyle and cancer prevention: Making choices that change cancer risk 3Health News:Lifestyle and cancer prevention: Making choices that change cancer risk 4Health News:Lifestyle and cancer prevention: Making choices that change cancer risk 5Health News:Lifestyle and cancer prevention: Making choices that change cancer risk 6Health News:M. D. Anderson research links diet, gardening and lung cancer risk 2Health News:Obesity, Diabetes Linked to Cancers 2Health News:Obesity, Diabetes Linked to Cancers 3Health News:Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia 2Health News:Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia 3Health News:Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia 4Health News:Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia 5Health News:Major Advance in the Observation of DNA Molecules 2
The Natural Selection family of specialty allografts is spinal concepts response to surgeon requests for spinal allograft devices to eliminate the need for painful autograft harvesting....
Transcranial vascular DWL doppler....
Transcranial vascular DWL doppler....
... Neurocare is a full-featured physiologic testing system offered ... contains many of the features of our flagship ... economical price. , ,The smaller size of the ... environment, the physician's office, a mobile service or ...
Medicine Products: